MTNB - Why Is Inflammatory Focused Matinas BioPharma Stock Trading Higher Today? | Benzinga
Wednesday, Matinas BioPharma Holdings Inc (NASDAQ: MTNB) announced results from a series of in vivo studies demonstrating successful oral delivery of two lipid nanocrystal (LNC)-formulated small single-strand oligonucleotides targeting inflammatory cytokines TNFα and IL-17A in animal models that mimic acute inflammatory responses seen in human diseases.
Earlier this year, Matinas established the in vitro potency of these proprietary oligonucleotides and their LNC formulations in knocking down their respective cytokine targets in cultured cells.
Both were ...